Meet Our Residents | Jumar Bioincubator

About
Incubator
- Meet Our Residents
Programs
Connect
Contact

Level 11, 655 Elizabeth Street, Melbourne VIC 3000

Email
hello@jumarbio.com

Nurturing biotech ventures

Meet our residents

121SEED is a new and exciting biotech company, which uses genetic technologies to produce new strains of biofortified wheat and other crops that enrich diets with essential micronutrients such as iron and zinc.

23Strands has developed a proven capability to deliver genome-wide DNA sequencing data to allow a more accurate understanding of complex diseases and to facilitate improvements in patient care. They are dedicated to utilising whole genome sequencing and Artificial Intelligence to unlock the power of your genetic code.

The Australian Dementia Network aims to advance the clinical knowledge for dementia prevention, treatment, and care, by bringing together Australia’s top researchers, to drive ongoing, high-quality research.

Alkira Bio uses its proprietary LASEREDD® technology platform to discover therapeutic antibodies directed against previously out of reach targets, pioneering new possibilities for drug discovery.

Arovella Therapeutics are developing an invariant natural killer T (iNKT) cell therapy platform licenced from Imperial College London to treat cancer. Their lead product is ALA-101, a CD19 targeting iNKT cell therapy to treat blood cancers. They are also developing therapies to treat gastric cancers, gastroesophageal junction cancers, and pancreatic Cancer.

Bio101 is a leading provider of financial services, transaction advisory and company secretarial services to the Healthcare sector. Since inception, Bio101 has been rapidly simplifying the finance and administration function, so Healthcare companies can spend more time focusing on the key elements of their business.

Biointelect is a leading strategic planning and commercialisation advisory firm for the life science sector. They enable the commercialisation of new therapies by helping clients to develop and drive integrated strategy, identify and evaluate new business opportunities and engage with the right partners.

The Centre for Biomedical Excellence (CBE) represents Australia's leading consultants across the biopharmaceutical sector, providing strategic solutions, encouraging excellence and increasing efficiency for firms across the Asia Pacific.

Celleo contributes intelligent production systems for the manufacture of Cell & Gene Therapies, with the mission of enabling Cell & Gene Therapies to deliver population-level health outcomes.

Denteric is a clinical stage company developing immunotherapies for the treatment of chronic inflammatory diseases caused by the bacteria Porphyromonas gingivalis. The lead indication is severe periodontitis, an oral health disease, the 6th most prevalent infectious disease in the world affecting one in three adults. The product aims to neutralise the toxins generated by the bacterium, in order to prevent inflammation from occurring.

exteRNA is developing small molecule therapeutics that target a unique aspect of RNA processing for the treatment of cancer.

Gallant Bio is an early-stage biotech company founded at the University of Melbourne, developing first-in-class brain-targeted therapeutics for the treatment of obesity and type 2 diabetes.

H3D's mission is to make custom-fit medical devices accessible for everyday people. They do this by providing B2B software to manufacturers/labs which unlocks rapid growth for their custom-fit businesses: Product #1 = AutoDesign, which automates CAD processes with AI and removes the need for highly skilled CAD technicians; Product #2 = Smartphone Scanning, which enables remote, non-intrusive capture of 3D digital impressions.

Immunosis are developing a pioneering diagnostic platform, with the aim to promptly identify immune dysfunctions, ensuring patients with immune deficiencies access crucial medications sooner. The proprietary genomic test analyses the patient’s own genetic information from a whole blood sample and generates a report for the treating clinician.

Inosi Therapeutics are developing therapies to address fibrosis, a condition associated with many chronic diseases where tissue damage leads to scarring and a loss of organ function. Their research involves first in class novel inhibitors targeting a central pathway in fibrosis and inflammation.

Latent Knowledge is building powerful research tools with artificial intelligence and natural language processing.

Misti is developing a first-in-class advanced medication delivery platform. Their innovative technology can control particle size, significantly improving the efficiency of delivering therapeutic biomolecules, including advanced drugs like mRNA, deep into the lungs. Misti's platform has the potential to revolutionise vaccine and therapy delivery, promising a positive impact on vulnerable populations worldwide.

NanoCube Health is an award winning, early-stage Melbourne-based medical technology commercialisation company developing potentially transformational cancer diagnostic and therapeutic technology for the early detection and treatment of pancreatic cancer.

Nelcanen is developing innovative therapeutics at the nexus of inflammation, autoimmunity and fibrosis.

Novoroo develops new therapeutic approaches to address neurological damage or disease in the central nervous system (CNS). Our novel LRP-focused science enables hope for treatment of conditions for which no current therapies exist.

Nutromic's breakthrough technology involves a patch consisting of DNA-based sensors coated onto the tips of microneedles that unlocks continuous and real-time monitoring of multiple clinically relevant targets for some of the deadliest disease states in the world.

PremieHealth is a deep tech company focused on improving the health outcomes of premature infants. Current care approaches have limited capacity to target critical physiological development, such as lung, gut, brain development, while optimising growth. Using our proprietary bioactive proteins and cutting-edge science, PremieHealth is pioneering next generation nutritional solutions that drive vital organ development, support timely life-stage programming of growth and transform care in Neonatal Intensive Care Units (NICUs) globally.

Proxima Bio are developing the next generation of medicines, cell surface degraders. Their technology provides new opportunities to target previously undruggable, disease-causing proteins, with powerful potential applications in autoimmune conditions and cancers.

Learn more

Qankorey are researching key technologies in prevention, screening, diagnosis and treatment of Alzheimer's disease. Their first product is a screening device that detects the risk of dementia and Alzheimer's disease. It is used to evaluate brain health status and assist doctors to decide whether further tests are required.

RAGE Biotech is developing novel therapeutics targeting the Receptor for Advanced Glycation End-products (RAGE) for patients with difficult-to-treat inflammatory disease. Their most advanced programme is an inhaled drug for lung diseases where chronic inflammation is a driver.

Remagine Labs are developing wearable, electronically controlled drug delivery products for the treatment of chronic conditions.

Resseptor Therapeutics is developing T-Cell Receptor (TCR) platform technology, engineering therapies for treatment of cancer, inflammation and autoimmune disease. Their pioneering platform technology enhances the immune system’s ability to identify and respond to tissues, malignancies and pathogens, potentially revolutionising treatments and changing the lives of people with autoimmune diseases, cancer and challenging inflammatory conditions.

SKYDD is pioneering the world's first natural spray product that utilizes IgY antibody engineering for active protection of the human respiratory tract against viruses.

Solubility is a team of highly skilled professionals with a long history in the specialized field of IP commercialisation law, commercial law, and R&D for scientific and creative businesses. Collectively, the firm has over 30 years’ experience in large and boutique private practices, as well as in-house experience at CSL Limited, the Australian Copyright Council and WIPO.

Symex Labs are building an innovative bio-sensor patch that can continuously track ovulation using hormone sensing in order to bring real independence and reliable insights about women's fertility.

Systematic Medicine's mission is to identify novel targets and therapeutic strategies to modulate the root causes of the ageing process.

Tessara Therapeutics are working on a technology called RealBrain®, which is based on 3D neural micro-tissues that mimic the human brain. RealBrain® is the first 3D neural model to combine all the essential requirements for drug discovery, including dense & heterogeneous neural networks, compatibility with high-throughput automation, short generation time, and high optical clarity.

Titan is a Contract Research Organisation (CRO). They assist biopharmaceutical clients in a range of activities from specific bid development to clinical protocol design to end-to-end clinical trials management, regulatory submission, and clinical implementation.

vivaLAB analyses the gut microbiome’s impact on metabolism, using data to create a personalised health algorithm that enhances gut and metabolic health.

Meet our alumni

oNKo-innate is a leading innate immune drug discovery and development company that has developed unique full-stack biology and modality platforms capable of discovering, validating and prosecuting new and emerging therapeutic targets.

Pacalis Therapeutics utilises intellectual property developed at Monash University to drive advancements in drug discovery. Their focus lies in developing a targeted agonist specifically designed for the serotonin receptor, with the aim of revolutionising the treatment of mental health conditions such as depression and PTSD.

Polyactiva is focused on providing unique biodegradable implants with sustained drug delivery to improve patient outcomes and quality of life for patients suffering from ophthalmic diseases such as glaucoma.

Turquoise Biotechnologies are a dedicated team of experienced scientists focused on harnessing the potential of extracellular vesicles (EVs) to create targeted drug and gene therapies. By employing advanced engineering techniques, they produce EVs designed to bind to specific cells and organs, customised for each particular disease. This approach enables the development of more effective therapies that address unmet medical needs while significantly reducing or even eliminating the undesirable side effects associated with systemic treatments. Their primary focus areas include hematological malignancies, solid tumors, and autoimmune diseases.

Stay up to date on resident news

Get Jumar resident news, biotech funding updates, and event invites straight to your inbox – monthly.